By entering this website, you confirm that you are a qualified researcher and that all materials are intended strictly for laboratory research purposes.
Products are not intended for human or veterinary use, diagnostic use, or consumption.
FREE SHIPPING OVER $250 · FREE BAC WATER OVER $150
We Accept
MT-2 research intersects with female-specific endpoints in dermatology and sexual-function studies, including HSDD (hypoactive sexual desire disorder) — its analog bremelanotide is FDA-approved in premenopausal women.
Pre-clinical research has measured eumelanin density and UV-response endpoints following melanocortin agonist administration in female models.
MC4R agonism is the mechanism underlying bremelanotide, FDA-approved for premenopausal HSDD — MT-2 is the structural parent compound studied in that research lineage.
Female pre-clinical models have examined melanocortin agonist effects on food intake and energy expenditure endpoints.
